普方生物制药（苏州）有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
ProfoundBio to Participate in the Bank of America 2023 Healthcare Trailblazers Private Company Conference 2023-10-05 20:00
ProfoundBio Announces Upcoming Scientific Presentations at SITC 2023 2023-09-28 20:00
ProfoundBio to Participate in the 21st Annual Morgan Stanley Conference 2023-08-28 20:00
ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic 2023-05-26 20:00
ProfoundBio Highlights Broad Antitumor Activity in Preclinical Models and Trial-in-Progress for PRO1184 at AACR 2023 Annual Meeting 2023-03-24 20:00
ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA "Study May Proceed" Letter for PRO1160, a CD70-Directed ADC 2023-01-03 20:00
ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer 2022-08-03 20:00
ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic 2022-06-02 20:00
ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer 2022-03-09 06:58
ProfoundBio Announces Presentation on Novel, Proprietary Linker-Drug Technology to Enable Antibody-Drug Conjugates (ADCs) with an Expanded Therapeutic Window at the AACR-NCI-EORTC International Conference 2021-10-08 11:39
ProfoundBio Announces Completion of More Than $55 million Series A Financing to Advance Novel Antibody-Drug Conjugate (ADC) Portfolio 2021-07-12 17:00
1